Two studies were performed to assess the entero-insular axis in simple obesity and the possible effect of variations in the level of circulating non-esterified fatty acids (NEFA) on one of the components of the entero-insular axis, glucagon-like peptide-1 [(7–36) amide]. In the first study, we compared the entero-pancreatic hormone response to oral carbohydrate in obese and lean women. Obese subjects demonstrated hyperinsulinaemia and impaired glucose tolerance but this was not associated with an increased secretion of either glucose-dependent insulinotropic polypeptide or glucagon-like peptide-1 (GLP-1). These findings therefore provide no support for the hypothesis that overactivity of the entero-insular axis contributes to the hyperinsulinaemia seen in obesity. Indeed, the plasma GLP-1 response to carbohydrate was markedly attenuated in obese subjects, confirming previous observations. In the second study, in which carbohydrate-stimulated GLP-1 responses were again evaluated in obese and lean women, circulating NEFA levels were modulated using either heparin (to increase serum NEFA) or acipimox (to reduce serum NEFA). Treatment with acipimox resulted in complete suppression of NEFA levels and in a markedly higher GLP-1 response than the response to carbohydrate alone or to carbohydrate plus heparin. We suggest that higher fasting and postprandial NEFA levels in obesity may tonically inhibit nutrient-mediated GLP-1 secretion, and that this results in attenuation of the GLP-1 response to carbohydrate. However, although serum NEFA levels post-acipimox were similarly suppressed in both lean and obese subjects, the GLP-1 response was again significantly lower in obese subjects, suggesting the possibility of an intrinsic defect of GLP-1 secretion in obesity. The reduction of GLP-1 levels in obesity may be important both in relation to its insulinotropic effect and to its postulated role as a satiety factor.
Skip Nav Destination
Article navigation
Research Article|
April 01 1999
Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids
L. RANGANATH;
1Department of Chemical Pathology, Epsom General Hospital, Epsom KT18 7EG, Surrey, U.K.
Correspondence: Dr L. Ranganath.
Search for other works by this author on:
F. NORRIS;
F. NORRIS
*School of Biological Sciences, University of Surrey, Guildford GU2 5XH, Surrey, U.K.
Search for other works by this author on:
L. MORGAN;
L. MORGAN
*School of Biological Sciences, University of Surrey, Guildford GU2 5XH, Surrey, U.K.
Search for other works by this author on:
J. WRIGHT;
J. WRIGHT
*School of Biological Sciences, University of Surrey, Guildford GU2 5XH, Surrey, U.K.
Search for other works by this author on:
V. MARKS
V. MARKS
*School of Biological Sciences, University of Surrey, Guildford GU2 5XH, Surrey, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society and the Medical Research Society © 1999
1999
Clin Sci (Lond) (1999) 96 (4): 335–342.
Citation
L. RANGANATH, F. NORRIS, L. MORGAN, J. WRIGHT, V. MARKS; Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids. Clin Sci (Lond) 1 April 1999; 96 (4): 335–342. doi: https://doi.org/10.1042/cs0960335
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |